vs
Side-by-side financial comparison of ACADIA PHARMACEUTICALS INC (ACAD) and IDEX Corporation (IEX). Click either name above to swap in a different company.
IDEX Corporation is the larger business by last-quarter revenue ($398.4M vs $284.0M, roughly 1.4× ACADIA PHARMACEUTICALS INC). ACADIA PHARMACEUTICALS INC runs the higher net margin — 96.3% vs 30.1%, a 66.2% gap on every dollar of revenue. On growth, IDEX Corporation posted the faster year-over-year revenue change (16.7% vs 9.4%). Over the past eight quarters, ACADIA PHARMACEUTICALS INC's revenue compounded faster (17.5% CAGR vs -29.4%).
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.
IDEX can refer to several things, including:International Defence Exhibition, a biennial arms and defense technology sales exhibition IDEX Corporation, a publicly listed company that makes fluidics systems and specialty engineered products Ideanomics, a publicly traded company that trades under the IDEX ticker symbol.
ACAD vs IEX — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $284.0M | $398.4M |
| Net Profit | $273.6M | $120.0M |
| Gross Margin | 90.8% | 99.9% |
| Operating Margin | 6.1% | 43.3% |
| Net Margin | 96.3% | 30.1% |
| Revenue YoY | 9.4% | 16.7% |
| Net Profit YoY | 90.3% | 25.7% |
| EPS (diluted) | $1.61 | $1.61 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q2 26 | — | $398.4M | ||
| Q1 26 | — | $407.7M | ||
| Q4 25 | $284.0M | $899.1M | ||
| Q3 25 | $278.6M | $878.7M | ||
| Q2 25 | $264.6M | $865.4M | ||
| Q1 25 | $244.3M | $814.3M | ||
| Q4 24 | $259.6M | $862.9M | ||
| Q3 24 | $250.4M | $798.2M |
| Q2 26 | — | $120.0M | ||
| Q1 26 | — | $128.3M | ||
| Q4 25 | $273.6M | $128.3M | ||
| Q3 25 | $71.8M | $127.8M | ||
| Q2 25 | $26.7M | $131.6M | ||
| Q1 25 | $19.0M | $95.5M | ||
| Q4 24 | $143.7M | $123.2M | ||
| Q3 24 | $32.8M | $119.1M |
| Q2 26 | — | 99.9% | ||
| Q1 26 | — | 94.9% | ||
| Q4 25 | 90.8% | 43.1% | ||
| Q3 25 | 92.2% | 44.5% | ||
| Q2 25 | 92.2% | 45.3% | ||
| Q1 25 | 91.7% | 45.3% | ||
| Q4 24 | 91.6% | 42.5% | ||
| Q3 24 | 92.5% | 44.3% |
| Q2 26 | — | 43.3% | ||
| Q1 26 | — | 45.0% | ||
| Q4 25 | 6.1% | 20.4% | ||
| Q3 25 | 12.8% | 21.1% | ||
| Q2 25 | 12.2% | 21.7% | ||
| Q1 25 | 7.9% | 17.4% | ||
| Q4 24 | 59.1% | 19.2% | ||
| Q3 24 | 12.6% | 21.0% |
| Q2 26 | — | 30.1% | ||
| Q1 26 | — | 31.5% | ||
| Q4 25 | 96.3% | 14.3% | ||
| Q3 25 | 25.8% | 14.5% | ||
| Q2 25 | 10.1% | 15.2% | ||
| Q1 25 | 7.8% | 11.7% | ||
| Q4 24 | 55.4% | 14.3% | ||
| Q3 24 | 13.1% | 14.9% |
| Q2 26 | — | $1.61 | ||
| Q1 26 | — | $1.71 | ||
| Q4 25 | $1.61 | $1.71 | ||
| Q3 25 | $0.42 | $1.70 | ||
| Q2 25 | $0.16 | $1.74 | ||
| Q1 25 | $0.11 | $1.26 | ||
| Q4 24 | $0.86 | $1.61 | ||
| Q3 24 | $0.20 | $1.57 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $177.7M | $586.2M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.2B | $4.0B |
| Total Assets | $1.6B | $6.9B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q2 26 | — | $586.2M | ||
| Q1 26 | — | $580.0M | ||
| Q4 25 | $177.7M | $580.0M | ||
| Q3 25 | $258.0M | $593.8M | ||
| Q2 25 | $253.6M | $568.2M | ||
| Q1 25 | $217.7M | $594.1M | ||
| Q4 24 | $319.6M | $620.8M | ||
| Q3 24 | $155.1M | $633.2M |
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | — | $1.8B | ||
| Q3 25 | — | $1.9B | ||
| Q2 25 | — | $1.9B | ||
| Q1 25 | — | $2.0B | ||
| Q4 24 | — | $2.0B | ||
| Q3 24 | — | $2.1B |
| Q2 26 | — | $4.0B | ||
| Q1 26 | — | $4.0B | ||
| Q4 25 | $1.2B | $4.0B | ||
| Q3 25 | $917.3M | $4.0B | ||
| Q2 25 | $822.4M | $4.0B | ||
| Q1 25 | $765.2M | $3.9B | ||
| Q4 24 | $732.8M | $3.8B | ||
| Q3 24 | $577.2M | $3.8B |
| Q2 26 | — | $6.9B | ||
| Q1 26 | — | $6.9B | ||
| Q4 25 | $1.6B | $6.9B | ||
| Q3 25 | $1.3B | $7.0B | ||
| Q2 25 | $1.2B | $6.9B | ||
| Q1 25 | $1.1B | $6.8B | ||
| Q4 24 | $1.2B | $6.7B | ||
| Q3 24 | $976.9M | $7.0B |
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | — | 0.45× | ||
| Q3 25 | — | 0.48× | ||
| Q2 25 | — | 0.46× | ||
| Q1 25 | — | 0.50× | ||
| Q4 24 | — | 0.52× | ||
| Q3 24 | — | 0.55× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-48.7M | — |
| Free Cash FlowOCF − Capex | — | $86.0M |
| FCF MarginFCF / Revenue | — | 21.6% |
| Capex IntensityCapex / Revenue | — | 4.4% |
| Cash ConversionOCF / Net Profit | -0.18× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $654.3M |
8-quarter trend — quarters aligned by calendar period.
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | $-48.7M | $209.5M | ||
| Q3 25 | $74.3M | $203.5M | ||
| Q2 25 | $64.0M | $161.7M | ||
| Q1 25 | $20.3M | $105.7M | ||
| Q4 24 | $40.4M | $172.6M | ||
| Q3 24 | $63.2M | $205.3M |
| Q2 26 | — | $86.0M | ||
| Q1 26 | — | $189.8M | ||
| Q4 25 | — | $189.8M | ||
| Q3 25 | $73.9M | $188.7M | ||
| Q2 25 | — | $146.9M | ||
| Q1 25 | — | $91.4M | ||
| Q4 24 | — | $157.1M | ||
| Q3 24 | $63.2M | $191.6M |
| Q2 26 | — | 21.6% | ||
| Q1 26 | — | 46.6% | ||
| Q4 25 | — | 21.1% | ||
| Q3 25 | 26.5% | 21.5% | ||
| Q2 25 | — | 17.0% | ||
| Q1 25 | — | 11.2% | ||
| Q4 24 | — | 18.2% | ||
| Q3 24 | 25.2% | 24.0% |
| Q2 26 | — | 4.4% | ||
| Q1 26 | — | 15.6% | ||
| Q4 25 | — | 2.2% | ||
| Q3 25 | 0.1% | 1.7% | ||
| Q2 25 | — | 1.7% | ||
| Q1 25 | — | 1.8% | ||
| Q4 24 | — | 1.8% | ||
| Q3 24 | 0.0% | 1.7% |
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | -0.18× | 1.63× | ||
| Q3 25 | 1.03× | 1.59× | ||
| Q2 25 | 2.40× | 1.23× | ||
| Q1 25 | 1.07× | 1.11× | ||
| Q4 24 | 0.28× | 1.40× | ||
| Q3 24 | 1.93× | 1.72× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACAD
| Nuplazid | $174.4M | 61% |
| Daybue | $109.6M | 39% |
IEX
Segment breakdown not available.
